Literature DB >> 26903186

Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica.

Karen C Broussard1, Theresa G Leung2, Ahmadreza Moradi2, Jennifer E Thorne3, Jo-David Fine4.   

Abstract

Autoimmune blistering diseases are a heterogeneous group of disorders that mostly affect the skin and mucous membranes. Occasionally, other organ systems may be involved, depending on the unique pathophysiology of each disease. Cicatricial pemphigoid, pemphigus vulgaris, and paraneoplastic pemphigus are distinct entities, but all have the potential to have cutaneous and ocular involvement. Awareness and early recognition of ocular involvement in these diseases is important given the increased risk for vision loss and blindness with delay in management. Several skin diseases may be associated with involvement of the external eye. The most common autoimmune diseases are cicatricial pemphigoid, pemphigus vulgaris, and paraneoplastic pemphigus.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26903186     DOI: 10.1016/j.clindermatol.2015.11.006

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  10 in total

Review 1.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

2.  Pemphigus Vulgaris-Associated Anterior Scleritis: A Case Study.

Authors:  Salim Alkeraye; Hanan Alsalman; Albanderi Alhamzah; Sulaiman M Alsulaiman
Journal:  Middle East Afr J Ophthalmol       Date:  2021-04-30

3.  Mucous Membrane Pemphigoid-Associated Malignancies: Case Series and a Brief Overview of the Literature.

Authors:  Michelangelo La Placa; Riccardo Balestri; Federico Tartari; Andrea Sechi; Francesca Ferrara; Camilla Loi; Annalisa Patrizi; Federico Bardazzi
Journal:  Dermatol Pract Concept       Date:  2019-04-30

Review 4.  Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy.

Authors:  Giovanni Paolino; Dario Didona; Giuseppe Magliulo; Giannicola Iannella; Biagio Didona; Santo Raffaele Mercuri; Elisa Moliterni; Michele Donati; Andrea Ciofalo; Guido Granata; Patricia Ranuzzi; Vincenzo Falasca; Stefano Calvieri
Journal:  Int J Mol Sci       Date:  2017-11-26       Impact factor: 5.923

Review 5.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

6.  Thiopurine S-methyltransferase and Pemphigus Vulgaris: A Phenotype-Genotype Study.

Authors:  Maral Mokhtari; Farzaneh Mostanbet; Saideh Nekooee Fard; Golsa Shekarkhar; Mozhdeh Sepaskhah; Maryam Sadat Sadati
Journal:  Iran J Pathol       Date:  2020-07-16

Review 7.  Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.

Authors:  Panagiotis Georgoudis; Francesco Sabatino; Nora Szentmary; Sotiria Palioura; Eszter Fodor; Samer Hamada; Hendrik P N Scholl; Zisis Gatzioufas
Journal:  Ophthalmol Ther       Date:  2019-01-29

Review 8.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 9.  Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.

Authors:  Hanan Rashid; Aniek Lamberts; Gilles F H Diercks; Hendri H Pas; Joost M Meijer; Maria C Bolling; Barbara Horváth
Journal:  Am J Clin Dermatol       Date:  2019-12       Impact factor: 7.403

10.  Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview.

Authors:  Celina Wakisaka Maruta; Denise Miyamoto; Valeria Aoki; Ricardo Gomes Ribeiro de Carvalho; Breno Medeiros Cunha; Claudia Giuli Santi
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.